DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Lars Fruergaard Jorgensen - 1 Thursday Jorgensen - 1 Jim Vondruska - 1 Jorgensen - 1 " Jorgensen - 1 Martin Lange - 1 Nikolaj Skydsgaard - 1 Jacob Gronholt - 1
Top related locs:
Danish Chicago , Illinois U.S Philadelphia Copenhagen London
Top related orgs:
Novo Nordisk - 1 COPENHAGEN - 1 REUTERS - 1 Wegovy - 1 Union - 1 American Heart Association - 1 Pedersen - 1 Thomson - 1

Search resuls for: "Thursday Jorgensen"


2 mentions found


☆ Novo Nordisk CEO sees US supply curbs on weight-loss drug Wegovy into 2024
  + stars: | 2023-08-10 | by ( Nikolaj Skydsgaard Jacob Gronholt-Pedersen | Nikolaj Skydsgaard | Jacob Gronholt-Pedersen | ) www.reuters.com   time to read: +2 min
Companies Novo Nordisk A/S FollowCOPENHAGEN, Aug 10 (Reuters) - Novo Nordisk's (NOVOb.CO) limits on U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug will last into next year even as the Danish drugmaker spends billions boosting output, its CEO told Reuters on Thursday. Earlier on Thursday, the company said it would continue to restrict U.S. supplies of starter doses of Wegovy as the company struggles to keep up with soaring demand. Novo has denied this, but when asked about this on Thursday Jorgensen said there may be shortages. The company expects to apply for regulatory approval for an expanded label indication in the U.S. and European Union later this year. "It'll take some time before we get it on label," Jorgensen said.
Persons: Lars Fruergaard Jorgensen, Thursday Jorgensen, Jim Vondruska, Jorgensen, " Jorgensen, Martin Lange, Nikolaj Skydsgaard, Jacob Gronholt, Josephine Mason, Jason Neely, Mark Potter Organizations: Novo Nordisk, COPENHAGEN, Reuters, REUTERS, Wegovy, Union, American Heart Association, Pedersen, Thomson Locations: Danish, Chicago , Illinois, U.S, Philadelphia, Copenhagen, London
☆ Novo Nordisk cuts some US supply of obesity drug Wegovy to cope with demand
  + stars: | 2023-05-04 | by ( Nikolaj Skydsgaard | ) www.reuters.com   time to read: +3 min
SummarySummary Companies Novo halves supply of Wegovy starter doses in U.S. "To safeguard continuity of care, the supply of the lower Wegovy dose strengths in the US will be reduced temporarily," Novo said in a statement. Novo has faced supply constraints for its hugely popular Wegovy drug as a result of overwhelming demand, and has invested massively in increasing supply. Supply of starter doses in the U.S. would be cut by around 50% for "some months," Jorgensen added. Credit Suisse analysts said they were not surprised by the move, given the level of demand for the drug.
0 next >>
Total: 2